Lung disease

#Clinical trial #DDII #Drug discovery #Immunology / Virology & Vaccines #Lung disease #Monoclonal antibodies #Psilocybin #UK

DDW Highlights: 14 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More

#Podcasts

Monoclonal antibody
#Lung disease #Monoclonal antibodies #University of Florida

Rare lung disease treated with monoclonal antibody

A proof-of-concept study led by a scientist at the University of Florida suggests a monoclonal antibody that targets a master regulator of inflammation, called NAMPT, could offer much-needed treatment for acute respiratory distress syndrome (ARDS).  In the study, a monoclonal antibody treatment called ALT-100 was used in… Read More

#News

#Bladder cancer #Covid-19 #Drug discovery #Heart disease #Lung disease #Oncology

This week in Drug Discovery (22-26 June) 

News round-up for 22–26 June by Bruno Quinney, Content Team at DDW.  This week, the Summer issue of DDW is now available to read. Elsewhere, researchers have uncovered clues explaining risks of heart disease, lung disease, Covid-19 and cancer.    The top stories: … Read More

#News

#Covid-19 #Genetic profiling #Lung disease #University of Edinburgh

Genetic variation increases Covid-19 and lung disease risk 

A genetic difference carried by nearly one in three could increase the risk of Covid-19 and lung disease, a new study shows.  Researchers at the University of Edinburgh found the genetic variant alters a newly discovered enzyme found in lung tissue, disrupting the function of a previously unknown protein. This… Read More

#News

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

DDW Highlights: 28 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More

#Podcasts

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

This week in Drug Discovery (20 – 24 April) 

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.  This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.  The top stories:   … Read More

#News

#Idiopathic pulmonary fibrosis #Lung disease #Respiratory

Digital lung ‘twins’ could predict drug efficacy in humans 

Digital lung ‘twins’ could help predict the efficacy of inhaled drugs in patients with respiratory problems.  Healthcare company Ebenbuild has developed lung digital twin technology, which uses patient-specific models to predict drug deposition.  According to a study published in Nature Communications Medicine, the validated technology… Read More

#News

#AI #Heart disease #Lung disease #Qureight

Qureight appoints Rebecca Simmons as COO 

Techbio company Qureight has appointed Rebecca Simmons as the company’s Chief Operating Officer.  Simmons will be responsible for scaling the company’s global business operations and leading sustainable growth initiatives. The appointment comes as Qureight aims to drive adoption and integration of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials for… Read More

#News

#AI #Heart disease #Lung disease #Qureight

Qureight appoints Dr Steven Bishop as CMO 

Techbio company Qureight has announced the appointment of Dr Steven Bishop as Chief Medical Officer.  Bishop previously served as Chief Data Officer for the company, which uses AI-powered CT imaging biomarkers and its clinical data management platform to advance understanding of lung and heart diseases.  As CMO, Bishop… Read More

#News

#AlveoliX #Francis Crick Institute #Lung disease #New approach methodologies (NAMs) #Organ-on-a-chip

First ‘lung-on-chip’ developed using genetically identical cells

Researchers at the Francis Crick Institute and AlveoliX have developed the first human ‘lung-on-chip’ model using stem cells taken from only one person.  These chips simulate breathing motions and lung disease in an individual, holding promise for testing treatments for infections like tuberculosis (TB) and delivering personalised… Read More

#Editor's Choice #News

#Celea Therapeutics #Idiopathic pulmonary fibrosis #Lung disease #PureTech #Respiratory

Celea Therapeutics launches into respiratory disease space

PureTech Health has announced the launch of a new founded entity Celea Therapeutics to deliver therapies for serious respiratory diseases.   Its lead programme, deupirfenidone (LYT-100), is a Phase III-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for the treatment of… Read More

#Business & Investment #News

Lungs
#Idiopathic pulmonary fibrosis #Lung disease #Phase II trial #Trevi Therapeutics

Drug significantly reduces common cough in IPF patients

Trevi Therapeutics has announced positive topline results from its Phase IIb CORAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF).   The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all… Read More

#News

#Clinical trials #Lung disease #Qureight

Synthetic study arms validate rare lung disease treatment

Qureight’s digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research. The study, presented at the American Thoracic Society, demonstrates significant clinical efficacy for Avalyn’s inhaled pirfenidone (AP01), a promising treatment for idiopathic… Read More

#News

Lungs
#Academic #Clinical trials #Fibrosis #Halo Biosciences #Hypertension #Lung disease #Stanford University

Study suggests new hope for pulmonary hypertension

Halo Biosciences has announced publication of results in Thorax from the Phase IIa SATURN study for patients with pulmonary hypertension and interstitial lung disease (PH-ILD). The study, conducted at Stanford University, evaluated 4-methylumbelliferone (4-MU) in patients with pulmonary hypertension, a highly progressive disease with significant unmet needs. The Phase IIa… Read More

#News

#Genetic diseases #Grifols #Lung disease #Phase II trial

Trials advance subcutaneous plasma therapy for AAT deficiency 

Grifols has finished recruiting the second cohort of its Phase I/II study evaluating two different doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%) as a subcutaneous (SC) option for the treatment of alpha1-antitrypsin (AAT) deficiency.  Cohort 2 patients will receive a 180mg/kg dose of SC Alpha-1… Read More

#News

Lungs
#Artificial intelligence (AI) #Idiopathic pulmonary fibrosis #Insilico Medicine #Lung disease #Phase II trial

Positive Phase II results for AI-created pulmonary fibrosis drug

Insilico Medicine reports improvement in patients with idiopathic pulmonary fibrosis (IPF) in a Phase IIa trial of ISM001-055. The drug, developed using generative AI, targets TNIK (Traf2- and NCK- interacting kinase) for the treatment of IPF. The topline results demonstrate that ISM001-055 is… Read More

#News